BPTH — Bio Path Holdings Income Statement
0.000.00%
- $0.62m
- $1.05m
Annual income statement for Bio Path Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 10.9 | 10.4 | 13.9 | 15.8 | 12 |
| Operating Profit | -10.9 | -10.4 | -13.9 | -15.8 | -12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -10.9 | -10.4 | -13.9 | -16.1 | -9.89 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -10.9 | -10.4 | -13.9 | -16.1 | -9.89 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -10.9 | -10.4 | -13.9 | -16.1 | -9.89 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -10.9 | -10.4 | -13.9 | -16.1 | -9.89 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -56.6 | -31 | -38.1 | -33.6 | -4.12 |